A Phase Ib, Open-label, Dose-escalation Study of the Safety and Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Ipatasertib (Primary) ; Docetaxel; Enzalutamide; Fluorouracil; Folinic acid; Oxaliplatin; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech
- 21 Nov 2017 Planned End Date changed from 31 Oct 2017 to 29 Jun 2018.
- 21 Nov 2017 Planned primary completion date changed from 31 Oct 2017 to 29 Jun 2018.
- 22 Mar 2017 Trial focus has been changed from AR to TU and AR.